Company intelligence / Profile preview
LongevityX
Philadelphia, Pennsylvania, United Stateslongevitybiotech.com ↗
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
01
Overview
Longevity Biotech's lead candidate, LBT-3627, is in Phase 1 trials for Parkinson’s Disease and is designed as a VIPR2 agonist synthetic peptide. The company reports disease-modifying approaches, but detailed clinical efficacy data is not disclosed in public sources.
- Therapeutic areas
- NeurologyEndocrinologyInfectious Diseases
- Modalities
- Synthetic peptide
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Michael J. Fox FoundationNational Multiple Sclerosis SocietyNational Institutes of HealthNational Science Foundation
04
Financials
- Market cap
- $272.3K
- Total revenue
- $1.9M
- Enterprise value
- $558.8K
Beyond the preview
Go deeper on LongevityX.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LongevityX.